← Back to all stories
Johns Hopkins Researchers Pioneer Nasal Vaccine to Combat Drug-Resistant Tuberculosis
Photo: Pharmacy Images / Unsplash
Scientists at Johns Hopkins Medicine are advancing a groundbreaking nasal vaccine designed to tackle tuberculosis, which remains the world's deadliest infectious disease. By combining two TB genes, the innovative approach trains the immune system to target bacteria that survive antibiotic treatment, offering new hope for preventing the disease's spread.
Scientists at Johns Hopkins Medicine are advancing a groundbreaking nasal vaccine designed to tackle tuberculosis, which remains the world’s deadliest infectious disease. By combining two TB genes, the innovative approach trains the immune system to target bacteria that survive antibiotic treatment, offering new hope for preventing the disease’s spread.